VILAZODONE ENHANCES THE ENDURANCE CAPACITY AND IMPROVES THE BIOLOGICAL CHANGES IN TREADMILL TEST IN RATS

Authors

  • Paula Alina FOTACHE “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Liliana MITITELU-TARTAU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Ionela Lacramioara SERBAN “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Monica HANCIANU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Cornelia Geanina MIRCEA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Ana-Maria PELIN “Dunărea de Jos” University Galati, Romania
  • Liliana Lacramioara PAVEL “Dunărea de Jos” University Galati, Romania

Abstract

The aim of our study was the evaluation of the vilazodone (VLZ) influence on the endurance capacity and biological modifications in rats subjected to forced exercise. Material and methods: For the experiment, 24 white Wistar rats, were randomly assigned into four groups. The substances were administered orally, in a single daily dose, for 14 consecutive days: Group 1 (Negative control): distilled water 0.3 mL/100g body without effort; Group 2 (Positive control): distilled water 0.3 mL/100g body subjected to effort; Group 3 (Mg): 200 mg/kg body magnesium chloride; Group 4 (VLZ): 20 mg/kg body vilazodone. The rats motor behavior and the endurance capacity were evaluated using the treadmill test, and some blood parameters, estimating the stress influence were assessed: The investigation protocol was approved and implemented according to recommendations of the “Grigore T. Popa” University of Medicine and Pharmacy Iasi Committee for Research and Ethical Issues. Results: The administration of VLZ resulted in a prolongation in distance traveled, an increase in the number of touches the opposite end of belt and a diminution in the number of delivered shocks. Moreover, it decreased the blood levels of glucose and cortisol, and increased the serum values of brain derived neurotrophic factor. The use of VLZ was accompanied by an intensification of anti-oxidant enzymes activity, respectively a decrease of the oxidative stress marker level in blood. Its effects were less intense, when compared to Mg. Conclusions: The treatment with VLZ improved the physical performances and the endurance capacity in this experimentally-induced stress model in rats. The use of this antidepressant drug recovered the biochemical changes and produced antioxidant effects in animals subjected to forced exercise in treadmill test.

Author Biographies

  • Paula Alina FOTACHE, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Ph.D. Student
    Faculty of Medicine
    Department of Morpho-functional Sciences (II)

  • Liliana MITITELU-TARTAU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Morpho-functional Sciences (II)

  • Ionela Lacramioara SERBAN, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Morpho-functional Sciences (II)

  • Monica HANCIANU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Pharmacy
    Department of Pharmaceutical Sciences (II)

  • Cornelia Geanina MIRCEA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Pharmacy
    Department of Pharmaceutical Sciences (II)

  • Ana-Maria PELIN, “Dunărea de Jos” University Galati, Romania

    Department of Pharmaceutical Sciences

  • Liliana Lacramioara PAVEL, “Dunărea de Jos” University Galati, Romania

    Department of Morphological and Functional Sciences

References

1. Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry 2017; 4: 409-418.
2. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2007; 173: 28-40.
3. Nagy C, Vaillancourt K, Turecki G. A role for activity-dependent epigenetics in the development and treatment of major depressive disorder. Genes Brain Behav 2018; 17: e12447: 1-9.
4. Uchida S, Yamagata H, Seki T et al. Epigenetic mechanisms of major depression: Targeting neuronal plasticity. Psychiat Clin Neurosci 2018; 72: 212-227.
5. Dirven BCJ, Homberg JR, Kozicz T, et al. Epigenetic programming of the neuroendocrine stress response by adult life stress. J Mol Endocrinol 2017; 59: R11-R31.
6. Branchi I. The double-edged sword of neural plasticity: increasing serotonin levels leads to both greater vulnerability to depression and improved capacity to recover. Psychoneuroendocrinol 2011; 37: 339-351.
7. Shi L, Wang J, Xu S, Lu Y. Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials. Drug Design Develop Ther 2016; 10: 3899-3907.
8. Sahli Z, Banerjee P, Tarazi F. The preclinical and clinical effects of vilazodone for the treatment of major depressive disorder. Expert Opin Drug Discov 2016; 11(5): 515-523.
9. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022567s012lbl.pdf
10. Papadakis MA, McPhee SJ. Current Medical Diagnosis & Treatment 2015, 54th Edition, McGraw Hill Education, 2015, USA.
11. Dale E, Bang-Andersen B, Sanchez C. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem Pharmacol 2015; 95: 81-97.
12. Zhang XF, Wu L, Wan DJ, et al. Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder. Neuropsychiatr Dis Treat 2015; 11: 1957-1965.
13. Wang XQ, Wang GW. Effects of treadmill exercise intensity on spatial working memory and long-term memory in rats. Life Sci 2016; 149: 96-103.
14. Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J Pharmacol Pharmacother 2010; 1(2): 87-93.
15. Elfving B, Plougmann PH, Wegener G. Detection of brain-derived neurotrophic factor (BDNF) in rat blood and brain preparations using ELISA: pitfalls and solutions. J Neurosci Methods 2010; 187(1): 73-77.
16. Directive 2010/73/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. http://eur-lex. europa. eu/ legal-content/ EN/TXT/ ?uri=CELEX:32010L0073.
17. McEwen BS. Protective and damaging effects of stress mediators: central role of the brain. Dialogues Clin Neurosci 2007; 8: 377-381.
18. Nakagawa Y, To M, Saruta J, et al. Effect of social isolation stress on saliva BDNF in rat. J Oral Sci 2019; 61(4): 516-520.
19. Aydemir O, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neuro-trophic factor levels in depressed patients: a preliminary study. Prog Neuropsycho-pharmacol Biol Psychiatry 2005; 29: 261-265.
20. JiaWen W, Hong S, ShengXiang X, et al. Depression- and anxiety-like behavior is related to BDNF/TrkB signaling in a mouse model of psoriasis. Clin Exp Dermatol 2018; 43(3): 254-271.
21. Zaletel I, Filipović D, Puškaš N. Hippocampal BDNF in physiological conditions and social isolation. Rev Neurosci 2017; 28(7): 775-792.
22. Hing B, Sathyaputri L, Potash JB. A comprehensive review of genetic and epigenetic mechanisms that regulate BDNF expression and function with relevance to major depressive disorder. Am J Med Genet B Neuropsychiatr Genet 2018; 177(2): 143-177.
23. Deyama D, Bang E, Kato T, et al. Neurotrophic and antidepressant actions of brain-derived neu-rotrophic factor require vascular endothelial growth factor. Biol Psychiatry 2019; 87(2): 143-152.
24. Bazzari AH, Bazzari FH. BDNF therapeutic mechanisms in neuropsychiatric disorders. Int J Mol Sci 2022; 23: 8417.

Additional Files

Published

2023-03-31